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Abstract
Background: Pemetrexed (MTA) plus cisplatin combination therapy is considered the standard of care for patients
with advanced non-small-cell lung cancer (NSCLC). However, in advanced NSCLC, the 5-year survival rate is below
10%, mainly due to resistance to therapy. We have previously shown that the fraction of mesenchymal-like,
chemotherapy-resistant paraclone cells increased after MTA and cisplatin combination therapy in the NSCLC cell
line A549.
Cytidine deaminase (CDA) and thymidine phosphorylase (TYMP) are key enzymes of the pyrimidine salvage
pathway. 5′-deoxy-5-fluorocytidine (5′-DFCR) is a cytidine analogue (metabolite of capecitabine), which is converted
by CDA and subsequently by TYMP into 5-fluorouracil, a chemotherapeutic agent frequently used to treat solid
tumors. The aim of this study was to identify and exploit chemotherapy-induced metabolic adaptations to target
resistant cancer cells.
Methods: Cell viability and colony formation assays were used to quantify the efficacy of MTA and cisplatin
treatment in combination with schedule-dependent addition of 5′-DFCR on growth and survival of A549 paraclone
cells and NSCLC cell lines. CDA and TYMP protein expression were monitored by Western blot. Finally, flow
cytometry was used to analyze the EMT phenotype, DNA damage response activation and cell cycle distribution
over time after treatment. CDA expression was measured by immunohistochemistry in tumor tissues of patients
before and after neoadjuvant chemotherapy.
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Results: We performed a small-scale screen of mitochondrial metabolism inhibitors, which revealed that 5′-DFCR
selectively targets chemotherapy-resistant A549 paraclone cells characterized by high CDA and TYMP expression. In
the cell line A549, CDA and TYMP expression was further increased by chemotherapy in a time-dependent manner,
which was also observed in the KRAS-addicted NSCLC cell lines H358 and H411. The addition of 5′-DFCR on the
second day after MTA and cisplatin combination therapy was the most efficient treatment to eradicate
chemotherapy-resistant NSCLC cells. Moreover, recovery from treatment-induced DNA damage was delayed and
accompanied by senescence induction and acquisition of a hybrid-EMT phenotype. In a subset of patient tumors,
CDA expression was also increased after treatment with neoadjuvant chemotherapy.
Conclusions: Chemotherapy increases CDA and TYMP expression thereby rendering resistant lung cancer cells
susceptible to subsequent 5′-DFCR treatment.
Keywords: Chemotherapy resistant, Pemetrexed, Cisplatin, Non-small cell lung cancer, Cytidine deaminase (CDA),
Thymidine phosphorylase (TYMP), 5′-DFCR, DNA damage
Background
Lung cancer remains the most common cancer type and
the leading cause of cancer deaths [1, 2]. Non-small cell
lung cancer (NSCLC) accounts for about 85% of all lung
cancers, with adenocarcinoma being the main histologic
subtype accounting for approximately half of the cases
[3, 4]. Chemotherapy is now recognized as an important
component of treatment for all stages of NSCLC, includ-
ing patients with completely resected, early-stage disease,
who benefit from improved survival rates after adjuvant
cisplatin-based chemotherapy [5]. The combination of
Pemetrexed (MTA, commercial name ‘Alimta’) with cis-
platin is recommended as gold standard therapy for
adenocarcinoma lung cancer and mesothelioma patients
[6] (reviewed in [7]).
MTA is a folic acid antagonist that inhibits the synthe-
sis of the precursor purine and pyrimidine nucleotides
and thus blocks DNA and RNA synthesis, thereby inter-
fering with cancer cell proliferation [8]. Cisplatin cova-
lently binds DNA and forms inter- and intra-strand
adducts, thereby blocking DNA replication and thus cell
division leading to apoptotic cell death or cellular senes-
cence [9]. However, the occurrence of intrinsic or ac-
quired resistance to chemotherapy is a major cause of
therapeutic failure in NSCLC leading to disease progres-
sion [10]. It has been postulated that cancer stem cells
(CSCs) are a subpopulation of cancer cells that feature
an increased tumor initiation capacity and are frequently
characterized by increased resistance to chemotherapy
[11]. However, in NSCLC, we demonstrated that tumor
initiation and chemotherapy resistance are features of
distinct cellular subpopulations, at least within the A549
cell line [12]. In the clinical setting, the occurrence of
chemotherapy resistance is a major obstacle, as non-
operable tumors will invariably develop resistance that
limits consecutive treatment approaches. Consequently,
the identification of the molecular mechanisms under-
lying the development of resistance to chemotherapy
offers a unique opportunity to target resistant cancer
cells and thus improve therapeutic options for cancer
patients.
Mitochondrial metabolism plays a pivotal role in can-
cer progression and chemotherapy resistance (reviewed
in [13, 14]). In detail, targeting mitochondrial energetics
and metabolism overcame drug resistance in acute mye-
loid leukemia (AML) [15, 16]. In lung cancer, high mito-
chondrial activity is related to chemotherapy resistance
[17, 18]. Thus, aberrant mitochondrial metabolism might
prove to be the Achilles heel of chemotherapy-resistant
cancer cells. Indeed, antibiotics targeting mitochondria
were used to eradicate CSCs, treating cancer like an in-
fectious disease [19].
Pyrimidine nucleotides can be synthesized via the de
novo or the salvage pyrimidine pathway. Depending on
the growth conditions, these pathways show different ac-
tivities in mammalian cells [20]. Dihydroorotate de-
hydrogenase (DHODH) is a key enzyme for the function
of the de novo pyrimidine synthesis pathway, whose ac-
tivity thus depends on the function of the mitochondrial
electron transport chain (ETC) [21]. In the salvage path-
way, pyrimidine nucleotides are formed by annealing
preformed free bases to phosphoribosyl pyrophosphates
(PRPP). For the salvage pathway, cytidine deaminase
(CDA) and thymidine phosphorylase (TYMP) are two
key enzymes, which catalyze the first and second step in
salvaging cytidine into uridine and uracil, respectively.
The cytidine analogue 5′-deoxy-5-fluorocytidine (5′-
DFCR) is the activated metabolite of the oral chemother-
apy drug capecitabine [22], which is used for the treat-
ment of different types of cancer including prostate,
renal, ovarian and colorectal cancer, but not for lung
cancer [23]. After passage through the intestinal mucosa,
capecitabine is first converted by carboxylesterase (CES)
into 5′-deoxy-5-fluoro-cytidine (5′-DFCR), mainly in the
liver [24]. 5′-DFCR is subsequently converted by CDA
and TYMP to 5-fluorouracil (5-FU) [22, 25]. As the
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active form of capecitabine or 5′-DFCR, 5-FU inhibits
the catalytic activity of the enzyme thymidine synthase
(TYMS) thereby blocking thymidine synthesis [25]. CDA
activity is crucial for capecitabine efficacy. Various poly-
morphisms of the CDA gene have been identified in the
population (reviewed in [26]), which are associated with
differences in capecitabine activity and efficacy [27].
In replicating cancer cells, blocked thymidine synthesis
leads to nucleotide pool imbalance, which subsequently
leads to DNA replication errors and activation of the
DNA damage response machinery, and, if not repaired,
to cell death (reviewed in [28]). Indeed, we previously
showed that blocking nucleotide synthesis by MTA
treatment results in the accumulation of persistent DNA
damage [18, 29]. Further, we found that prolonged pre-
treatment with MTA enhances the anticancer efficacy of
subsequent cisplatin treatment [30]. This study further
revealed the existence of a chemotherapy-resistant sub-
population in the NSCLC cell line A549. In a subsequent
study, we showed that the parental, non-treated A549
cell line contains phenotypically distinct subpopulations.
In detail, holoclone cells are characterized by a stem-like
epithelial phenotype and feature an increased tumor ini-
tiation capacity compared to paraclone cells, which fea-
ture a mesenchymal phenotype and are highly resistant
to chemotherapy [12]. In addition, we found that epithe-
lial to mesenchymal (EMT)-related plasticity exists be-
tween the A549 subpopulations. EMT is a trans-
differentiation program essential for numerous develop-
mental processes during embryogenesis enabling epithe-
lial cells to lose cell polarity and cell–cell adhesion and
to concomitantly attain mesenchymal characteristics,
such as enhanced migration and invasion [31]. Cons-
quently, EMT plays a crucial role in cancer metastasis
and drug resistance [32, 33].
CDA is most commonly expressed in bone marrow
and liver, and more moderately or even undetectably in
other tissues [34]. Databases describe CDA as a cytoplas-
mic protein [35] consistent with the recycling of free py-
rimidines from the cytoplasm [26]. CDA expression is
epigenetically silenced in approximately 60% of cancer
cell lines and tissue specimen [36]. However, treatment
with 5-Aza-2′-Deoxycytidine (5-Aza-dC), a DNA meth-
yltransferase activity inhibitor, significantly increases
CDA expression in cancer cell lines derived from breast,
lung ovarian and melanoma tumors with a low initial
CDA expression level. In addition, restored CDA protein
expression by 5-Aza-dC treatment led to a significant in-
crease in gemcitabine resistance indicating that plasticity
in nucleotide metabolism is linked with chemotherapy
resistance. Indeed, it has been proposed that blocking
cancer cell metabolism might increase the efficiency of
chemotherapeutic agents (reviewed in [37]. However, to
the best of our knowledge, it is not kown whether
chemotherapy-induced plasticity of nucleotide metabol-
ism can be exploited to overcome chemoresistance in
lung cancer.
In this study, we aimed to identify an inhibitor of
mitochondrial metabolism that preferentially targets
chemotherapy-resistant A549 paraclone cells [12]. 5′-
DFCR was found to selectively inhibit the growth of
chemotherapy-resistant lung cancer cells featuring in-
creased CDA and TYMP expression. Interestingly, we
found that treatment with MTA and cisplatin, either
alone or in combination, increased expression of CDA
and TYMP in a schedule-dependent manner. Conse-
quently, the schedule-dependent treatment with 5′-
DFCR specifically targets resistant cancer cells that have
survived the preceding MTA and cisplatin combination
therapy.
Materials and methods
Cell culture and media
Human NSCLC cell lines A549, H358, H441, H2009,
PC-9, H1993, H2228 and H3122 (CCL-185) were ob-
tained from ATCC (American Type Culture Collection;
Manassas, VA, USA) and cultured in media as recom-
mended by ATCC (RPMI-1640 supplemented with 9%
FBS, 1% Penicillin/Streptomycin solution or DMEM-F12
medium supplemented with 9% FBS, 1% Penicillin/
Streptomycin and 1% L-Glutamine) at 37 °C in a humidi-
fied 5% CO2 incubator. A549 Rho0 cells were cultured
in DMEM-F12 medium with high glucose, supplemented
with 9% FBS, 1% P/S, 1% L-Glutamine, 1 mM sodium
pyruvate, 50 μg/ mL uridine and 50 ng/ mL ethidium
bromide. Cell lines were DNA fingerprinted and tested
for mycoplasma contamination as described before [12,
30, 33].
Cell viability assay
A549 holoclone and paraclone cells were seeded at 1000
cells per well in 96-well plates. After overnight incuba-
tion, different concentrations of the specified inhibitors
of mitochondrial metabolism were added and cells were
incubated for another 6 days (Table S1, Additional file 3).
Cell viability was measured by using the Acid Phosphat-
ase (APH) Assay according to the protocol described
previously [38]. Changes in absorbance were recorded in
a Tecan Reader Infinite M1000.
siRNA-based gene expression silencing
siRNA-based knockdown of CDA mRNA expression
(siCDA) was achieved by 3 unique 27mer siRNA du-
plexes (CDA Human siRNA Oligo Duplex [Locus ID
978], OriGene). Transfection of siRNAs was performed
with Lipofectamine 2000 according to the manufac-
turer’s instructions.
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Clonogenic assay
A549 holoclone and paraclone cells, as also parental
A549 cells transfected with either control siRNA
(siCTRL) or siCDA, were seeded into 6-well plates at a
density of 10′000 cells/well. Different concentrations of
5′-DFCR or 100 μM tetrahydrouridine (THU) were
added into plates after cells attached for 6-day treat-
ment. Subsequently, the media were removed, and cell
colonies were gently washed with PBS and stained by 1%
crystal violet solution (in 50% Ethanol), which was pre-
pared from 2.3% crystal violet solution (HT901-8FOZ,
Sigma). After 30 min-staining, the dye solution was pi-
petted back for recycling and excess dye was gently
rinsed off with tap water. After the plates were air-dried,
pictures were captured with a standard photo camera.
Crystal violet-stained cells were dissolved in 10% acetic
acid solution (2 mL/ well) for 30 min on a shaker and
the concentration of the extracted dye (100 μL/ well)
was quantified with a spectrophotometer at 590 nm [39].
CDA activity assay
CDA activity assay was performed by cytidine deaminase
activity assay kit (fluorometric, BioVision). Two hun-
dred microliter assay buffer was added into 3 × 106 cells.
Dounce homogenizer was used to prepare the solution
for activity measurement. Measurement was performed
based on the protocol of CDA activity assay kit.
Western blot analysis
NSCLC cells were seeded into 6-well plates (0.15–0.45 ×
106 cells per well, depending on the doubling time of the
different cell lines). After 1 day (i.e. day 0), 1 μM MTA
or concomitant chemotherapy treatment was used to
treat cells. On day 2, 10 μM cisplatin was added for
schedule chemotherapy treatment, e.g. 48 h of MTA pre-
treatment followed by 24 h of combined MTA and cis-
platin treatment. Cells were lysed by RIPA buffer
containing 1× protease and phosphatase inhibitor cock-
tail at different timepoints. Protein concentration was
measured by Pierce™ BCA Protein Assay Kit. Equal
amounts of protein lysates (11–23 μg/ lane) were re-
solved by SDS-PAGE. Then the bands were transferred
onto nitrocellulose membranes. The membrane was
firstly blocked in Intercept® (TBS) Blocking Buffer for 1
h at room temperature and then blotted with specific
primary antibodies (Table S1, Additional file 3) at 4 °C
overnight with shaking. Tris Buffered Saline (TBS) with
0.2% Tween-20 was used to wash the membrane. IRDye
680LT-conjugated goat anti-mouse IgG and IRDye
800CW-conjugated goat anti-rabbit IgG from Li-COR
Biosciences were used at 1:5000 dilutions. Finally, signals
of membrane-bound secondary antibodies were imaged
using the Image Studio Lite System, also for image
analysis.
Drug response and senescence-associated β-galactosidase
assay
To determine how different treatment strategies affect
cell growth (Fig. 4a), 1 × 106 A549 or 1.3 × 106 H358
cells were seeded into 150 mm× 20mm tissue culture-
treated dishes. Starting at the day after seeding, i.e. at
day 0, cells from one dish per treatment were harvested
using TrypLE as negative control whereas 1 μM MTA
was added to the remaining dishes. On day 2, 10 μM cis-
platin was used to treat cells for 24 h. In this study, cells
were treated for 3 days with 5′-DFCR at a final concen-
tration of 200 μM. Cells were harvested by TrypLE at
different time points after treatment. Cell numbers were
determined using a hemocytometer and 0.1% trypan
blue for dead cell exclusion. H358 cells were washed in
phosphate-buffered saline and processed for analysis by
flow cytometry as described below. To determine cell
growth during the extended recovery period, A549 cells
were harvested at day 13 of the recovery period,
reseeded at a density of 0.2 × 106 cells per 150 mm × 20
mm plate and cell numbers were subsequently deter-
mined as described above. Experiments for A549 were
repeated independently three times. H358 cells were not
harvested or reseeded, as cell numbers were still very
low. Experiments for H358 cells were repeated inde-
pendently two times.
Senescent cells were visualized by using the senescence
β-galactosidase staining kit. In detail, 0.75 × 106
chemotherapy-resistant A549 cells at recovery day 13
were reseeded in tissue culture treated 6-well dishes in-
cluding treatment group untreated (1), schedule (3),
schedule + 5′-DFCR D0(4) and schedule + 5′-DFCR
RD2(5) (Fig. 4a). After cells were attached on the next
day, A549 cells were fixed and stained according to the
manufacture protocol. An inverted light microscope
equipped with a 20x objective was used for visualizing
and imaging senescent cells. Senescent cells were
counted with the plugin ‘Cell Counter’ of the ImageJ
software.
Flow cytometry (FC) analysis
H358 cells were harvested as described above ‘Drug re-
sponse assay’. An untreated control was included at
every time point. A549 cells were harvested at 72 h after
transfection with siCTRL or siCDA. If available, 1 × 106
cells were harvested and washed with phosphate-
buffered saline (PBS). First, cells were stained with anti-
bodies against the cell surface markers, e.g. EpCAM or
CD90. Then, cells were fixed with IC fixation buffer so-
lution and permeabilized with 0.1% Triton X 100 in PBS
containing 1% FBS. Prior to intracellular staining,
permeabilized cells were incubated in 200 μL of PBS
supplemented with 10% FBS and 0.25% Fc Receptor
Binding Inhibitor Functional Grade Monoclonal
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Antibody for 5 min at room temperature and washed in
PBS containing 1% FBS. Intracellular staining was per-
formed with AF546-conjugated Anti-Vimentin, PerCP-
eFluor 710-conjugated anti-p-H2AX Ser139, AF-488 con-
jugated anti-Sox 2, or anti-CDA overnight on a rotating
wheel (3 rpm) at 4 °C, protected from light. On the next
day, cells were washed twice with PBS with 2% FBS and
stained with secondary antibody AF-488-conjugated
anti-Rabbit on a rotating wheel (3 rpm) for 30 min, to
stain anti-CDA antibody. At the end, cells were wahed
twice with PBS with 2% PBS and resuspended in 0.5 μg/
ml DAPI in PBS containing 2% FBS to stain DNA. Geo-
metric Mean Fluorescence intensity (GMFI) was mea-
sured on a LSR2 upgraded flow cytometer (BD
Bioscience) and 10′000 events were recorded. FCS files
were analyzed using FlowJo V10 (Tree Star, Inc. (Ash-
land, OR, USA)).
Analysis of openly available data and public databases
(TCGA), gene ontology terms analysis
The sequencing data containing the whole genome ex-
pression analysis of the three different types of A549
clones, e.g. holo-, mero-, and paraclones was previously
published by our group [12]. In detail, this data is openly
available as additional information to our aforemen-
tioned publication https://doi.org/10.1016/j.neo.2018.09.
008. Kaplan Meier plot website (www.kmplot.com) was
used to generate CDA and TYMP gene expression and
survival curves based on survival data of lung cancer pa-
tients treated with chemotherapy. Level 3 and 4 tran-
scriptomic and reverse-phase protein array data of
cancer patients were obtained from The Cancer Genome
Atlas (TCGA) cBioPortal (https://www.cbioportal.org/)
and The Cancer Proteome Atlas (TCPA) [40]. A
normalization step was applied to normalize between
samples before downstream analysis using the methods
in DESeq and Limma R packages. The gene expression
and corresponding survival data were extracted for cor-
relation and prognostic analysis using the corresponding
packages in R (version 3.6.0) (‘corrplot’ and ‘Hmisc’
packages for correlation analysis; ‘maxstat’, ‘survival’ and
‘survminer’ packages for prognostic analysis). A549 holo-
clone and paraclone RNA- seq data was used generate
volcano curve by R package, showing all mitochondrial
gene (MitoCarta).
EMT (epithelial Mesenchymal transition) and MET
(Mesenchymal epithelial transition) induction in A549 and
H358 cells
A549 cells (0.1 × 106 / well) and H358 (0.25 × 106 / well)
were seeded into 6-well plates. 0.5 ng/ μL (5 days) and
0.25 ng/ μL (4 days) TGF-β were used to treat A549 and
H358 cells for EMT induction, respectively. Similarly,
A549 cells (0.05 × 106/ well) and H358 cells (0.1 × 106/
well) were seeded into 6-well plates. Tenmicrometre
SB431542 was used to treat A549 (3 days) and H358 (5
days) cells for MET induction. Protein was harvested
after treatment, as described in part ‘Western Blot
analysis’.
Patients
Initially 118 patients with resected carcinomas of the
lung were included in the study. These cases were
resected at the Inselspital Bern and diagnosed at the In-
stitute of Pathology Bern between 2000 and 2016. After
exclusion of 3 cases due to missing tumor in the TMA
punches, 115 patients were included for the evaluation
of tumoral CDA expression. The study cohort consisted
of 55 patients who received a systemic treatment prior
to the resection. Due to the retrospective character of
the case collection, patients therapy was heterogeneous,
as previously described [41]. In addition, five cases
resected and diagnosed at the Hunan Cancer Hospital
were included in this study. To assure a homogeneous
study cohort, only the 49/55 patients who received at
least one cycle of platinum-based neoadjuvant chemo-
therapy were included for further analyses. The biologic-
ally matched control cohort consisted of 60 patients
with carcinomas of the lung without systemic treatment
prior to the resection but presence of mediastinal lymph
node metastases (pN2) to guarantee a similar disease
stage with the study cohort before administration of
neoadjuvant therapy.
Tissue and immunohistochemistry
A next generation Tissue Microarray (ngTMA) was con-
structed as previously described using formalin fixed
paraffin embedded tissue [42]. Immunohistochemistry
(IHC) was performed at room temperature with the fully
automated staining system BOND RX® (Leica Biosys-
tems). CDA staining was conducted using a polyclonal
antibody against human CDA(Tris, 1:500) as shown in
Table S1, Additional file 3.
CDA expression on tumor cells was evaluated accord-
ing to Mameri et al. using H-score, the product of stain-
ing intensity and frequency of positive tumor cells [36].
Figure S14 (Additional file 1) examplifies the applied in-
tensity scoring. Additionally, we evaluated the expression
patterns of CDA in a dichotomous manner differentiat-
ing between a homogeneous and heterogeneous expres-
sion. CDA expression was assessed considering all TMA
cores to account for unequal numbers of tumor cells.
Only cores with at least 10 vital tumor cells were eligible
for evaluation.
In 25 patients, tumor tissue pre- and post-
chemotherapy was available for analysis. Whole sections
of formalin-fixed paraffin-embedded adenocarcinoma
tissue were used for CDA-IHC [43].
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Statistics
Statistical analyses were performed using GraphPad
Prism 6.03 (GraphPad Software Inc., http://www.
graphpad.com) unless otherwise indicated. In all studies,
data represent biological replicates (n) and are depicted
as mean values ± standard deviation (SD) or mean
values ± standard error of the mean (SEM) as indicated
in the figure legends. Comparison of mean values was
conducted with two-tailed Student’s t test and two-way
ANOVA with Tukey’s multiple comparisons test as indi-
cated in the figure legends. In all analyses, p values less
than 0.05 were considered statistically significant.
The Mann-Whitney-U test, Fisher’s exact test and
crosstabs were used to identify significant differences of
the H-Score, intensity and frequencybetween the cohorts
of patient samples. Spearman correlation was performed
to investigate correlation of the CDA expression with
clinico-pathological parameters and Wilcoxon signed-
rank test for paired samples. A two-sided asymptotic p ≤
0.05 was considered significant. The statistical analysis
was performed using the R software (version 4.0.2,
https://cran.r-project.org).
Results
Chemotherapy resistant A549 paraclone cells feature
increased CDA expression and are sensitive to 5′-DFCR
We took advantage of the morphologically and pheno-
typically distinct A549 subpopulations as a tool for
screening mitochondrial metabolism inhibitors specific-
ally targeting chemotherapy resistant subpopulations.
Based on RNA-seq data of A549 holoclone versus para-
clone cells (Figure S1D, Additional file 1), we selected
six inhibitors that block various nodes of the mitochon-
drial metabolism (Figure S1A-C, Additional file 1), in-
cluding the mitochondrial complex I inhibitor IACS-
010759 (Figure S1C, Additional file 1), the pyruvate de-
hydrogenase (PDHα1) inhibitor CPI-613, the antibiotic
tigecycline, which inhibits protein synthesis in mito-
chondria, the dihydroorotate dehydrogenase (DHODH)
inhibitor teriflunomide, the CDA inhibitor tetrahydrour-
idine (THU) and the cytidine analogue 5′-deoxy-5-fluor-
ocytidine (5′-DFCR). Of those six inhibitors,
teriflunomide inhibits the de novo pyrimidine synthesis
pathway, while THU and 5′-DFCR interfere with the
pyrimidine salvage pathway (Figure S1B, Additional file
1). THU was selected as an inhibitor due to the in-
creased expression of CDA in chemotherapy resistant
A549 paraclone compared to holoclone cells (Figure
S1D, Additional file 1). Surprisingly, only 5′-DFCR spe-
cifically targeted chemotherapy-resistant paraclone cells
(Figure S2, Additional file 1). In detail, 5′-DFCR treat-
ment significantly inhibited the proliferation and colony
formation of paraclone cells, whereas holoclone cells
were not affected (Fig. 1b and c, respectively). We
speculated that the growth inhibitory effect of 5′-DFCR
on paraclonal cells was related to the high CDA and
TYMP expression levels (Fig. 1d and g) and CDA activ-
ity levels (Fig. 1h), respectively, which convert 5′-DFCR
to the toxic metabolite 5-FU in two sequential reaction
steps (see also Fig. 1a). Indeed, treatment with the CDA
inhibitor THU was able to rescue not only short-term
survival but also long-term colony formation capacity of
paraclonal cells from 5′-DFCR toxicity (Fig. 1e and f, re-
spectively). In addition, siRNA-mediated silencing of
CDA expression not only reduced CDA protein levels
(Fig. 1i) but also significantly rendered both parental and
paraclonal A549 cells more resistant to 5′-DFCR treat-
ment (Fig. 1i and j, respectively). In other words, the
sensitivity of chemotherapy-resistant paraclonal cells to
5′-DFCR is dependent on functional CDA.
EMT-induction increases CDA and TYMP expression
Basal CDA expression levels are higher in mesenchymal
paraclone compared to epithelial holoclone A549 cells
(Fig. 1d and g). Silencing of CDA expression in parental
A549 cells induced a phenotypic shift towards a more
epithelial morphology (Figure S3E, Additional file 1),
which was associated on the molecular level with an
EMT-related plasticity, i.e. increased SOX2 and CD90
expression indicative of a hybrid-E/M status (Figure S2A
and B, Additional file 1). We previously observed bidir-
ectional plasticity during in vitro and in vivo cultivation
of cellular A549 subtypes, e.g. holoclone cells can
undergo an EMT to convert to a meroclonal and subse-
quently a paraclonal state whereas paraclone cells can
undergo MET to convert to a meroclonal and subse-
quently to the holoclonal state [12]. Thus, we speculated
that the CDA expression levels are positively correlated
with the cellular EMT status. We took advantage of the
publically available TCGA database containing 517 cases
of primary lung adenocarcinoma tumors and performed
an in-silico mRNA expression analysis of CDA, TYMP
and several EMT markers (Fig. 2c). CDA and TYMP
mRNA expression levels were positively correlated with
mesenchymal transcription factors TWIST2, SNAIL1/2,
and FN1, VIM and AXL, which are encoding the struc-
tural proteins fibronectin and vimentin and the AXL re-
ceptor tyrosine kinase, respectively, which are all
associated with a mesenchymal phenotype [12]. Besides,
the mRNA transcription levels of CDA and TYMP were
negatively correlated with the epithelial transcription
markers SOX2 and NKX2–1, and CDH1, e.g. the gene
encoding the epithelial marker E-cadherin (Fig. 2c). In
agreement, the analysis of publicaly available single cell
RNA-seq data of lung adenocarcinoma PDX revealed
that CDA expression levels significantly correlated with
the EMT- and invasion-score (Fig. 2d/e, respectively).
Our extended in-silico analysis revealed that the
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Fig. 1 (See legend on next page.)
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increased expression of CDA and TYMP in 36
chemotherapy-treated patients was significantly corre-
lated with a poor prognosis (Figure S4A-B, Additional
file 1). Further analysis based on the overall survival of
502 lung adenocarcinoma patients, revealed that low ex-
pression of CDA correlated with a better survival, while
TYMP expression levels did not correlate with survival
(Figure S4C-D, Additional file 1). Thus, high basal CDA
expression levels are positively correlated with a higher
EMT status, e.g. a mesenchymal phenotype, and in-
creased resistance to chemotherapy.
To further investigate the relation between CDA and
TYMP expression levels and EMT induction, we used
TGF-β and the TGF-β inhibitor SB431542 to induce
EMT and MET, respectively (Fig. 2a-b). Treatment of
A549 and H358 cells with TGF-β resulted in a more
(See figure on previous page.)
Fig. 1 High expression of CDA and TYMP associates with chemoresistance and sensitivity to 5′-DFCR. a Pyrimidine pathway, CDA (cytidine
deaminase) and TYMP (thymidine phosphorylase) are key enzymes in pyrimidine salvage pathway; b High expression of CDA and TYMP sensitized
A549 paraclone cells to 5′-DFCR. Left, APH cell viability assay, right, colony formation assay; c CDA inhibition rescued A549 para clone cells from
the sensitivity to 5′-DFCR, left APH cell viability assay; right, colony formation assay. d Immunoblotting of CDA and TYMP in different A549
subpopulations P: parental A549; Holo, Mero and Para represent A549 holo, mero and para clone cells, respectively. Ordinary two-way ANOVA
was used for significance anlysis of drug response curves (Fig. 1b/e/j/k, ****P < .0001). A two-sided t-test was used for the significance anlysis of
the CDA activity assay (Fig. 1h, **P < .01)
Fig. 2 CDA and TYMP expression correlated with EMT pathway. a CDA and TYMP expression increased after TGF-β induced EMT transition in
A549 and H358 cells, which is showed by immunoblotting (b) CDA and TYMP decreased after TGFβ inhibitor SB431542 induced MET transition. c
Correlation matrix between CDA, TYMP expression and EMT transcription factors among lung adenocarcinoma from TCGA database. d, e
Correlatin analysis between EMT status and CDA expression based on single cell sequencing of lung adenocarcinoma patient PDX samples.
Ordinary two-way ANOVA was used for significance anlysis (*P < .05, **P < .01, ***P < .001, ****P < .0001; n.s., not significant)
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mesenchymal phenotype, e.g. E-cadherin expression de-
creased whereas Vimentin expression reciprocally in-
creased (Fig. 2a). TGF-β treatment increased CDA and
TYMP expression in both cell lines. After induction of
MET by treatment with SB431542, Vimentin expression
slightly decreased in the cell line H358, while a slight in-
crease in E-cadherin expression was detected in the cell
line A549 (Fig. 2b). After MET induction, TYMP expres-
sion slightly decreased in A549 cells whereas CDA ex-
pression significantly decreased in H358 cells. In a
summary, CDA and TYMP expression positively correl-
ate with the EMT status in lung adenocarcinoma patient
samples. In addition, the induction of EMT, even in the
absence of accumulation of DNA damage, can increase
CDA and TYMP expression. In other words, CDA ex-
pression is increased in the mesenchymal compared to
the epithelial status.
Chemotherapy treatment increases CDA and TYMP
expression and activity in lung adenocarcinoma cell lines
This study revealed that CDA and TYMP protein ex-
pression is increased in chemotherapy-resistant para-
clone cells compared to holoclone cells (Fig. 1d). We
previously showed that treatment of the parental A549
cell line with concomitant MTA and cisplatin combin-
ation therapy increased the fraction of paraclone-like
cells and that this effect could be further enhanced if
MTA treatment preceedes cisplatin treatment by 48 h
[30]. Therefore, we speculated that MTA and cisplatin
combination therapy might increase CDA and TYMP
expression, which could be exploited to target
chemotherapy-resistant subpopulations by treatment
with 5′-DFCR. Indeed, schedule-dependent MTA and
cisplatin combination therapy increased CDA and
TYMP expression in A549 cells over time, with a dra-
matic increase in expression levels 2 days after cessation
of the drug treatment, i.e. at recovery day 2 (RD2)
(Fig. 3a). CDA and TYMP expression were also in-
creased after single MTA or cisplatin treatment, al-
though concurrent combination therapy further
augmented the effect (Fig. 3b, d, g). Interestingly, basal
CDA and TYMP expression levels varied dramatically in
different NSCLC cell lines including the KRAS mutant
cell lines A549, H358, H441 and H2009, as well as KRAS
wild type (WT) cell lines PC-9, H1993, H3122 and
H2228 (Figure S5A, Additional file 1). Our extended in
silico analysis that includes 189 lung cancer cell lines
and patient samples revealed only a weak correlation be-
tween CDA expression levels and KRAS mutational sta-
tus (Figure S5E-F, Additional file 1). Nevertheless,
schedule-dependent MTA and cisplatin combination
therapy increased CDA and TYMP expression over time
also in the other tested KRAS mutant cell lines, e.g.
H358 and H441 (Fig. 3a, Figure S6A-C, Additional file
1). However, CDA and TYMP expression did not in-
crease after MTA and cisplatin treatment in the KRAS
mutant cell line H2009 (Figure S5B-C, Additional file 1).
In the tested KRAS wild-type cell lines, this chemother-
apy treatment also resulted in changes of CDA and
TYMP expression levels over time, but the response was
more heterogeneous (Fig. 3e-f and Figure S5D, Add-
itional file 1). In detail, CDA expression levels peaked at
the end of the treatment, e.g. at day 3 (D3), in the cell
lines PC-9 and H3122 whereas the CDA levels were
highest during the recovery phase (RD1–3) in the cell
line H1993. In summary, in cell lines featuring low basal
CDA expression levels, e.g. A549, H1993 and H3122
(see Figure S5A), chemotherapy treatment clearly in-
creased the relative CDA expression levels over time.
The relative changes and the time course of CDA ex-
pression levels were more heterogeneous in cell lines
featuring high basal CDA levels, e.g. H358, H441,H2009,
PC9 and H2228.
Subsequently, we evaluated how the drugs individually
or as concomitant combination therapy affect CDA and
TYMP expression levels over time (Fig. 3b-g, and Figure
S6D-E, J-K, Additional file 1). In the KRAS-mutant cell
lines A549, H358 and H441 and also in the KRAS-wild
type cell lines H1993 and H3122, single MTA treatment
generally increased expression of CDA and TYMP dur-
ing the recovery phase (RD1–5), which was also ob-
served after single cisplatin treatment and was most
pronounced after concomitant combination treatment
(Fig. 3b-g). Indeed, CDA activity was significantly in-
creased in A549 cells at recovery day 5 after combin-
ation therapy compared to untreated control (Fig. 3c). In
the cell line PC-9, TYMP expression was not detectable,
and CDA expression was increased by single MTA treat-
ment whereas cisplatin or concomitant therapy did not
significantly affect CDA expression levels.
In summary, chemotherapy treatment generally in-
creased CDA and TYMP expression and activity in lung
adenocarcinoma cell lines. However, CDA and TYMP
expression levels did not increase after treatment in the
PC-9 cell line, in which TYMP protein expression was
undetectable, suggesting that the ability to augment
CDA expression after treatment may depend on the
baseline genetic or metabolic state of the individual cell
line.
Efficient triple combination to overcome chemotherapy
resistance in lung adenocarcinoma cells
We aimed to test whether the chemotherapy-induced in-
crease in CDA/TYMP expression (Fig. 3) can be
exploited to target the remaining, chemotherapy-
resistant subpopulations by subsequent treatment with
5′-DFCR (high expression of CDA conferred sensitivity
to 5′-DFCR, see Fig. 1). We performed five treatment
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strategies including untreated (1), 5′-DFCR alone (2),
schedule-dependent chemotherapy treatment either
alone (3), with 5′-DFCR addition at D0 (4) or with 5′-
DFCR addition at RD2 (5) (Fig. 4a). Treatment with 5′-
DFCR alone did arrest cell growth only temporarily
compared to control cells over time, as the A549 and
H358 cells resumed their growth after drug removal
(Fig. 4b and d). Treatment 3/4/5 all initially reduced the
cell numbers and halted cell growth during the early re-
covery phase (RD1-RD15 and RD3-RD18 for A549 and
H358, respectively). Pretreatment of H358 cells with
chemotherapy augmented the efficiency of subsequent
treatment with 5′-DFCR compared to concomitant
treatment (Fig. 4d). After reseeding cells at RD13, pre-
treatment with chemotherapy significantly increased the
efficiency of subsequent 5′-DFCR treatment compared
Fig. 3 Chemotherapy treatment increases CDA and TYMP expression in a subset of lung adenocarcinoma cell lines. a Immunoblotting of CDA
and TYMP in KRAS mutant cell lines A549, H358 and H441 after schedule-dependent MTA-cisplatin combination therapy (48 h MTA-pretreatment)
at different time points. b Immunoblotting of CDA and TYMP in KRAS mutant cells after single MTA, cisplatin, and concurrent combination
treatment at different time points. c Increased CDA enzyme activity of A549 cells after MTA and cisplatin combination treatment, two-sided
student’s t test (* p < 0.05); d, g Quantification analysis of CDA and TYMP expression in A549 cells after single MTA, cisplatin and concomitant
combination treatment compared to untreated control (see Fig. 3b), N = 2, two-sided student’s t test (* p < 0.05, **p < 0.01, ***p < 0.001). e
Inmmunoblotting of CDA and TYMP in non-KRAS mutant cell lines PC-9, H1993 and H3122 after schedule-dependent MTA-cisplatin combination
therapy (48 h MTA-pretreatment) at different time points; f Immunoblotting of CDA and TYMP in non-KRAS mutant cell lines PC-9, H1993 and
H3122 after single MTA, cisplatin and concurrent combination treatment at different time points; h Quantification analysis of CDA expression in
PC-9 after single MTA, cisplatin and concurrent combination treatment, N = 2, two-sided student’s t test (* p < 0.05)
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Fig. 4 Efficient triple combination to treat KRAS-mutant lung adenocarcinoma cells in vitro. a Treatment strategies in vitro 5 treatments
Untreated, 5′-DFCR alone, schedule, schedule + 5′-DFCR and schedule + 5′-DFCR were included. RD: recovery days. b and c: A549 cell growth
curve after different treatments, N = 3, on RD21, 2-sided student’s t test was used (*p < 0.05, *** p < 0.001). d and e: H358 cell growth curves after
different treatments, N = 2, 2-way ANOVA was used to compare different treatment groups (* p < 0.05). f: representative images of cells acquired
by phase contrast-based microscopy at day 13 of the recovery phase (RD13) after senescence associated β-galactosidase staining (200×
total magnification)
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to concomitant treatment in both A549 and H358 cell
lines (Fig. 4c & e). Additionally, colony formation was
completely abolished after chemo-pretreatment and sub-
sequent 5′-DFCR treatment at RD2. In contrast, colony
formation was relatively resistant to chemotherapy alone
or in combination with concomitant treatment with 5′-
DFCR (Figure S7, Additional file 1). In summary, treat-
ment with chemotherapy results in increased CDA/
TYMP expression during the recovery phase thereby
sensitizing lung cancer cells to subsequent 5′-DFCR
treatment.
Pretreatment of 5′-DFCR treatment with chemotherapy
augments senescence induction and accumulation
persistence of DNA damage
We aimed to understand on the molecular level how
pretreatment with chemotherapy augments the effi-
ciency of subsequent 5′-DFCR treatment. Visual exam-
ination after treatment revealed that a significant
fraction of the cells displayed morphological changes
that are associated with senescence, namely increased
cell size and flattened shape (reviewed in [44]). The frac-
tion of cells, which stained positive for senescence-
associated β-galactosidase activity increased after treat-
ment with chemotherapy compared to untreated cells
(Fig. 4f and Figure S7C, Additional file 1). Interestingly,
the fraction of senescent cells was reduced after triple
combination therapy compared to chemotherapy alone.
However, the percentage of senescent cells was highest
after treatment with chemotherapy followed by subse-
quent treatment with 5′-DFCR at RD2 (Fig. 4f and Fig-
ure S7C, Additional file 1). Detected by flow cytometry,
increased forward (cell size) and side (cellular granular-
ity) scatter intensity (F/S-high) is an additional charac-
teristic associated with senescence (reviewed in [45]).
This flow cytometric analyses revealed that the highest
ratio of F/S-high versus F/S-low in H358 cells was ob-
served after combined treatment with chemotherapy and
5′-DFCR, irrespective of the time point of 5′-DFCR
addition (Figure S8H, Additional file 1). A classical hall-
mark of senescence is the induction of a terminal cell
cycle arrest [46]. It has been shown that the increase in
cell size of cancer cells after cisplatin treatment leads to
shifts in the DAPI signal [30]. Therefore, we individually
analyzed the cell cycle distribution of the F/S-high and
F/S-low populations according to our previously estab-
lished protocol ([29, 30], see also Figure S8, Additional
file 1). Indeed, treatment with chemotherapy alone in-
duced a dramatic accumulation in S-phase in both, F/S-
low and F/S-high cells (Figure S9, Additional file 1).
However, the level of cells in the G1-phase of the cell
cycle returned to almost pretreatment levels in the F/S-
low subpopulation whereas most cells of the F/S-high
subpopulation remained in S- or the G2/M-phase during
the extended recovery phase, e.g. RD11–26 (Figure S9,
Additional file 1). Compared to treatment with chemo-
therapy alone, no obvious differences in the cell cycle
distribution was detectable after concomitant treatment
with chemotherapy and 5′-DFCR. However, after treat-
ment with chemotherapy and subsequent 5′-DFCR
treatment at RD2, the percentage of cells in the in S- or
the G2/M-phase remained high during the extended re-
covery phase even in the F/S-low subpopulation (Figure
S9, Additional file 1).
We previously demonstrated that accumulation of per-
sistent DNA damage leads to a cell cycle arrest and in-
duction of senescence in lung cancer cells [29, 30, 47].
Thus, we determined the effect of the different treat-
ment regimens on H2AX phosphorylation (ɣH2AX), a
marker of DNA damage ([48], see also Figure S8, Add-
itional file 1). As expected, treatment with chemotherapy
induced H2AX phosphorylation in the majority of cells
(Fig. 5, d3). During the late recovery phase (RD11–26),
the level of ɣH2AX remained very high in all F/S-high
cells (with the exception of cells in the G2-phase after
concomitant triple therapy in which H2AX phosphoryl-
ation levels return to normal at RD26) (Fig. 5, right
panels). In contrast, after treatment with chemotherapy
alone, levels of DNA damage continuously decreased in
cells of the F/S-low subpopulation during the late recov-
ery phase (Fig. 5, left panels). After treatment with the
concomitant triple therapy, ɣH2AX levels also decreased
during the late recovery period in F/S-low cells, most
prominently in the G1-phase (Fig. 5, left panel). How-
ever, on recovery day 26 (RD26) after combined chemo-
therapy and subsequent 5′-DFCR treatment, ɣH2AX
was not only detectable in almost 100% of the F/S-high
cells but also in roughly 90% of the F/S-low cells (Fig. 5,
bottom panels). Thus, chemotherapy and subsequent 5′-
DFCR treatment on RD2 resulted in the persistence of
DNA damage even during the extended recovery period.
In summary, treatment with chemotherapy and subse-
quent 5′-DFCR treatment at RD2 leads to an increased
level of persistent DNA damage associated with the in-
duction of a senescent phenotype compared to simultan-
eous treatment.
The therapy-induced increase in CDA expression is
associated with a hybrid-EMT phenotype
Next, we aimed to uncover the pathways regulating the
increase of CDA and TYMP expression after treatment
with chemotherapy (see Fig. 2). We previously showed
that treatment with chemotherapy induces an epithelial
mesenchymal transition (EMT) in lung cancer cells [29,
30, 32, 43]. Thus, we hypothesized that the
chemotherapy-induced activation of EMT might drive
the increased in CDA and TYMP expression during the
recovery phase. Expression of E-cadherin and Vimentin
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Fig. 5 5′-DFCR at recovery day 2 after schedule-dependent treatment induced persistent DNA damage. Accumulation DNA damage within each
cell cycle phase was determined in F/S-low and F/S-high cells separately. Cell cycle phases and H2AX phosphorylation levels were gated as
described in supplementary Figure S8. Basal ɣH2AX was set at 10% as ɣH2AX high in untreated controls and used for normalization among
experiments as described in the material and methods section. Data are represented as mean ± SD (N = 2)
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were previously monitored as surrogate markers to de-
termine the epithelial and mesenchymal status of cancer
cells during EMT, respectively [49]. MTA and cisplatin,
either as mono- or concomitant combination treatment,
increased E-cadherin expression during the early recov-
ery phase (RD1–5) in both, A549 and H358 cells
(Fig. 6a-b and e-f, respectively). Changes in Vimentin ex-
pression levels were more variable. However, combin-
ation treatment clearly induced a shift towards a more
mesenchymal phenotype, which was apparent by micro-
scopic analysis in both, the A549 and H358 cell lines
(Fig. 6g & Figure S12D, Additional file 1). Indeed, a
long-term time course experiment revealed that E-
cadherin and Vimentin expression levels changed dy-
namically over time (Fig. 6c-d). Concurrent high expres-
sion levels of E-Cadherin and Vimentin indicated either
the co-existence of both mesenchymal and epithelial
subpopulations or the appearance of a subpopulation of
cells featuring a hybrid-EMT phenotype as described by
us before [12]. Indeed, our FACS analysis revealed that
treatment with 5′-DFCR induced a hybrid-EMT pheno-
type in H358 cells (Fig. 7). After treatment with 5′-
DFCR, the fraction of cells featuring a hybrid-EMT
phenotype reached maximal levels at RD11 and subse-
quently declined during the late recovery phase (RD18–
26) (Fig. 7). In contrast, the fraction of hybrid-EMT cells
Fig. 6 Chemotherapy induced EMT status changes along with the increase of CDA and TYMP. a Immunoblotting of EMT markers E-cadherin and
vimentin in A549 cells after single MTA and cisplatin and concurrent combination treatment. For comparison, the corresponding immunoblotting
of CDA, TYMP and β-actin are also provided (same images as in Fig. 3b, top panel). b Graphical categorization of the immunoblots shown in A,
N = 3, data are represented as mean. c Immunoblotting of CDA, TYMP and the EMT markers E-cadherin and vimentin in A549 cells after schedule-
dependent MTA and cisplatin combination treatment. d Graphical categorization of the immunoblots shown in C, N = 3, data are represented as
mean. e Immunoblotting of EMT markers E-cadherin and vimentin in H358 cells after single MTA and cisplatin and concurrent combination
treatment. For comparison, the corresponding immunoblotting of CDA, TYMP and β-actin are also provided (same images as in Fig. 3b, second
panel from the top). f Graphical categorization of the immunoblots shown in E, N = 2, data are represented as mean. g A549 cells undergo
morphological changes after MTA and cisplatin combination treatment at recovery day 5 (RD5), (40×, total magnification)
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Fig. 7 EMT phenotype plasticity of H358 cells treated with different regimens. Left panel: Flow cytometry analysis of H358 cells on recovery day
11 (RD11) and recovery day 26 (RD26) after Schedule(3), Schedule + 5′-DFCR (4), and Schedule + 5′-DFCR RD2(5) treatment. EpCAM and Vimentin
were used as EMT markers to distinguish different states of EMT. Cells were featured with epithelial (EpCAM+/Vimentin−), mesenchymal (EpCAM−/
Vimentin+), hybrid (EpCAM+/Vimentin+), and negative (EpCAM−/Vimentin−). Righ panel: EMT phenotype at different timepoints after treatment
with different regimens. Data are represented as mean ± SD (N = 2)
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only reached maximal levels at RD18 after triple com-
bination irrespective of the time point of 5′-DFCR
addition. However, the disappearance of cells featuring a
hybrid-EMT phenotype was significantly delayed after
pretreatment with chemotherapy and subsequent 5′-
DFCR treatment compared to concomitant treatment
(Fig. 7, right panels).
We hypothesized that the therapy-induced hybrid-
EMT phenotype might be positively associated with the
high CDA expression and DNA damage levels during
the late recovery phase. In agreement with our western
blot results (Fig. 6e-f), our FACS analysis confirmed a
time dependent increase of CDA expression and H2AX
phosphorylation levels after combination therapy (Figure
S11A-B, Additional file 1). The decrease of CDA-
positive cells over time was delayed after triple therapy
independent of the time point of 5′-DFCR treatment
compared to chemotherapy alone (Figure S11A, Add-
itional file 1). In the untreated H358 cell line, the frac-
tion of CDA-high and ɣH2AX-high cells was higher in
the hybrid subpopulation compared to the other three
subpopulations (Figure S11C and D, respectively, Add-
itional file 1). After long-term recovery (RD26) from
treatment with chemotherapy and subsequent 5′-DFCR
treatment at RD2, the fraction of CDA-high and
ɣH2AX-high cells remained high in all except the sub-
population, which stained negative for EPCAM and
VIMENTIN (Figure S11E and F, respectively, see also
Figure S10I-J, Additional file 1).
In summary, all tested treatment regimens induced a
hybrid-EMT phenotype that is associated with high
CDA and ɣH2AX expression levels (Figure S10I-J and
S11, Additional file 1). Pretreatment with chemotherapy
and subsequent 5’DFCR treatment significantly enhances
the persistence of this phenotype during the late recov-
ery phase (Fig. 7 and S10I-J, Additional file 1).
Chemotherapy elicits patient-specific changes in CDA
expression in tumor tissue samples
In order to evaluate the clinical significance of our find-
ing that chemotherapy increased CDA and TYMP ex-
pression in lung cancer cells and thereby conferred
sensitivity to 5′-DFCR treatment, we investigated if
chemotherapy treatment also increased CDA and TYMP
expression in the tumor tissues of lung cancer patients.
In agreement with our western blot results (Fig. 1d), ex-
pression of CDA was lower in A549 holoclone compared
paraclone cells (Figure S14E & F, respectively, Additional
file 1). Next, we examined CDA expression in pre- and
post-chemotherapy samples (Figure S14, Additional file
1). CDA expression of the study cohort (post-chemo-
therapy, mean rank = 57.49) and the control cohort (pri-
mary resected) were not significantly different (W =
1516, p = 0.780) (Additional file 2). There was no
significantly difference between the two cohorts neither
for the intensity score nor the frequency score (Fig. 8a
and Figure S13, Additional files 1 and 2). CDA expres-
sion did neither correlate with pT considering all sam-
ples nor with the proportion of residual tumor cells, pN,
latency between neoadjuvant chemotherapy and resec-
tion or duration of neoadjuvant chemotherapy in sam-
ples after neoadjuvant therapy. We also analyzed a
paired cohort of 25 patients where matched pre- and
post-chemotherapy samples of the same tumor were
available. In the paired cohort, 7/25 (28%), 12/25 (48%)
and 6/25 (24%) showed increased, equivalent or de-
creased H-scores. No significant difference was found
between pre- and postneoadjuvant tissue (W = 44, p =
0.944). Three paired cases showed a considerable in-
crease versus 2 cases with marked CDA decrease in the
post-chemotherapy tumor tissues (Fig. 8c). The pre-
neoadjuvant tissue of 9/25 (36%) originated from lymph
nodes. Both of the two samples with marked decrease in
CDA expression after neoadjuvant therapy were com-
pared to preneoadjuvant tissue from lymph nodes sug-
gesting a potential role of the inflammatory
microenvironment on CDA expression in adenoacarci-
nomas of the lung.
In summary, the changes in CDA expression levels in-
duced by chemotherapy vary significantly between can-
cer patients. Furthermore, CDA staining is extremely
heterogeneous between different sites within a tumor
and between different patients (Figure S15, Additional
file 1), which led to difficulties in evaluating the effect of
chemotherapy on CDA expression in patients. Neverthe-
less, our analysis reveals the existence of a subgroup of
patients in whom CDA expression in cancer cells in-
creases dramatically after chemotherapy.
Discussion
CDA expression has a bimodal distribution, which is
associated with the cellular EMT status
In this study, we discovered that the chemotherapy-
resistant, mesenchymal-like A549 paraclonal subpopula-
tion features increased CDA and TYMP expression
compared to the epithelial holoclonal subpopulation
(Fig. 1d). Further, the A549, H1993 and the H3122 cell
lines featured low but nevertheless detectable CDA
epression levels whereas CDA expression levels were sig-
nificantly higher in the remaining cell lines investigated
in this study. Thus, we conclude that the CDA expres-
sion levels of the cell lines included in this study resem-
ble a bimodal distribution. In agreement with these
findings, our in silico analysis also revealed a binominal
distribution of CDA expression in the cohort of 189 lung
cancer cell lines and in primary lung cancer patient tis-
sue samples (Figure S5E/F, respectively, Additional file
1). In agreement, an extensive in silico analysis revealed
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that CDA expression is downregulated in about 60% of
cancer cell lines and tissues and that the low CDA ex-
pression levels correlate with CDA promoter methyla-
tion [36]. Changes in promoter methylation of genes
either associated with a epithelial or a mesenchymal
phenotype is a hallmark of EMT (reviewed in [50]). In-
deed, we found that CDA and TYMP expression levels
can be modulated by treatment with TGF-β and
SB431542, which induce either an EMT or a MET, re-
spectively (Fig. 2). Historically, it was postulated that
EMT describes the bimodal transition of an epithelial to
a mesenchymal state (reviewed in [50]). Thus, our find-
ings of a bimodal distribution of the CDA expression
levels in cell lines can be explained by the close associ-
ation of CDA expression and the EMT status. However,
our in silico analysis revealed a positive association of
CDA experession with the EMT and the invasion status
at the single cell, level revealing that CDA expression is
very heterogenous even within the same tumor (Fig. 2d-
e), which was confirmed by our study at the protein level
in lung cancer patient tissue samples (Fig. 8, and Figure
S14–15, Additional file 1). Further, a very recent analysis
of lung cancer on the single cell level revealed eight dis-
tinct EMT-states and significant differences between
EMT and MET trajectories [51]. Indeed, our analysis in-
dicated that the therapy-induced increase in CDA ex-
pression levels is associated with the hybrid-E/M
phenotype (Figure S11, Additional file 1). Further, the
increase of CDA and TYMP expression after treat-
ment with chemotherapy was more pronounced in
KRAS mutant lung cancer cells (Fig. 3). Interestingly,
KRAS mutant cancer cells that are dependent or
addicted to the KRAS oncogene are more likely to be
associated with an epithelial phenotype, while those
that are independent of KRAS adopt a mesenchymal
phenotype (reviewed in [52]). However, additional ex-
periments will be required to unravel the exact mo-
lecular mechanism responsible for the positive
association with CDA expression and EMT status and
whether the capacity to increase CDA expression
upon treatment is associated with the KRAS addition
status.
Fig. 8 Chemotherapy exerts different effects on CDA expression in patient tumor tissues. a: Comparison of CDA expression between patient
tumor tissue resected after neoadjuvant chemotherapy and primary resected tumors, Independent-samples Mann-Whitney U test, Wilcoxon W:
1516, Asymptotic sig. (2-sided test: 0.780); b: Samples with marked decrease of CDA expression after neoadjuvant chemotherapy, both
preneoadjuvant specimen are lymph node biopsies. Patient 1 H-Score preneoadjuvant of 9 and postneoadjuvant of 1, Patient 2 H-Score
preneoadjuvant of 9 and postneoadjuvant of 4; c: Samples with marked increase of CDA expression after neoadjuvant chemotherapy. Patient 1
H-Score preneoadjuvant of 1 and postneoadjuvant of 9, Patient 2 H-Score preneoadjuvant of 0 and postneoadjuvant of 9, Patient 3 H-Score
preneoadjuvant of 2 and postneoadjuvant of 4
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Therapy-induced stress increases CDA expression
Our study also revealed the treatment-induced increase
in CDA and TYMP expression is dependent on the che-
motherapeutic drug, the treatment schedule and also on
the genetic and EMT-status of the individual cancer cell.
In detail, CDA and TYMP expression level changes were
more pronounced after cisplatin treatment compared to
single MTA treatment and were further augmented by
the combination therapy. Nevertheless, our in vitro ex-
periments revealed a remarkable increase in CDA and
TYMP expression during the recovery phase after treat-
ment with chemotherapy in most of the studied cell
lines. In agreement, a recent study, which analyzed the
therapy-induced evolution of human lung cancer by
single-cell RNA sequencing (scRNA-seq), revealed that
TYMP expression was increased in progressive meta-
static lung cancer compared to the NSCLC biopsy sam-
ples that were obtained from patients before initiating
systemic targeted therapy [53]. The recent scRNA-seq
study [53] further revealed that individual tumor and
cancer cells exhibit marked therapy-induced plasticity
and substantial molecular diversity. Nevertheless, the
fraction of cells featuring high TYMP expression was
significantly increased in on-therapy progressive disease
compared to samples obtained before targeted therapy.
Thus, the increased CDA and TYMP expression might
not be a specific response to DNA damaging chemother-
apy but might be a more general stress response associ-
ated with EMT. In agreement with this hypothesis, it has
been recently reported that the CDA-dependent deox-
yuridine salvage may function as anti-oxidant to protect
pancreatic cancer cells against ROS [54]. Specifically, it
has been suggested that uridine has an activating effect
on the mitochondrial ATP-dependent potassium chan-
nel (mitoKATP) thereby reducing H2O2 levels in the
mitochondria and thus the development of oxidative
stress [55]. Indeed, it has been shown that CDA-
dependent deoxyuridine can relieve ROS-induced endo-
plasmic reticulum stress to promote cancer cell survival
[54]. Thus, increased CDA expression might augment
cancer cell survival via the protective effect of
(deoxy)uridine.
It was shown before that gene expression reprogram-
ming during EMT is regulated mainly by epigenetic
modifications [56]. Further, it has been shown that the
CDA-dependent nucleotide salvage pathway displays
substrate selectivity, effectively protecting newly synthe-
sized DNA from the incorporation of epigenetically
modified forms of cytosine [57]. Thus, we speculate that
the deoxycytidine salvage pathway is the mechanism by
which epigenetically modified nucleotides are excluded
from introduction into newly synthesized DNA [58]. Ac-
tive excision of epigenetically modified nucleotides by
the DNA damage response machinery and subsequent
repair synthesis with unmodified nucleotides will result
in global DNA demethylation. Thus, we speculate that
the CDA-dependent demethylation might significantly
contribute to chemotherapy-induced EMT and, thereby,
to the development of chemotherapy resistance. The
regulation of EMT is complex, and further studies will
be needed to clarify whether and, if so, how CDA is re-
lated to the chemotherapy-induced epigenetic changes
underlying the development of chemotherapy-resistance.
Exploiting therapy-induced CDA expression to specifically
target resistant cancer cells
We found that treatment with chemotherapy results in
increased CDA/TYMP expression during the recovery
phase thereby sensitizing lung cancer cells to subsequent
5′-DFCR treatment. Interestingly, Ishitsuka and col-
leagues previously showed that various cytostatic drugs
had increased the level of TYMP expression in WiDr
human colorectal cancer xenografts, which was most
pronounced by Taxol, Taxotere and Mitomycin C [59].
In this study, they also showed that Taxol/Taxotere en-
hanced the Capecitabine and 5’DFCR efficacy in human
cancer xenografts. This group also showed that the
TYMP activity and improved efficacy of Capecitabine in
various human cancer xenografts can be induced by dif-
ferent treatment regimen including ionizing radiation
[60], oxaliplatin [61], and chemoendocrine therapy [62].
Thus, our findings are in agreement with the existing lit-
erature indicating that the efficacy of Capecitabine
in vivo, respectively with 5’FDCR in vitro, can be aug-
mented by combination therapy. To the best of our
knowledge, our study shows for the first time that the
increased effect of the combination therapy can be fur-
ther enhanced by a schedule dependent adjustment of
the treatment regimen. Interesting in this context,
already in 2009, a case report was published, which de-
scribed a patient with metastatic lung adenocarcinoma
with clear partial response to capecitabine after several
lines of chemotherapy [63].
A limitation of our study is that we investigated only a
limited number of possible combinations of the triple
combination therapy. For example, the effect of the
exact treatment schedule on the treatment efficiency has
to be elucidated in more detail. It has been shown previ-
ously that the treatment schedule significantly affects
treatment efficacy. In detail, the exposure of A549 cells
to MTA and subsequent cisplatin treatment reduced cell
survival, whereas the inversed treatment regimen or the
simultaneous application of MTA and cisplatin resulted
in antagonistic effects [64]. In our study, concomitant
treatment with 5′-DFCR, MTA, and cisplatin resulted in
a slightly antagonistic anti-cancer growth effect com-
pared to MTA and cisplatin combination therapy alone.
Only the addition of 5′-DFCR during the recovery
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phase, e.g., once CDA expression levels have increased,
further augmented the anti-cancer effect compared to
MTA and cisplatin combination therapy alone. There-
fore, also in an in vivo or the clinical setting, the favor-
able anti-cancer effect of triple combination therapy will
most likely depend on the precise treatment planning. In
addition, as with any therapy consisting of multiple
agents, extensive in vivo experiments will be required to
determine the optimal concentration of each agent to
maximize anti-cancer efficacy while limiting toxicity.
Thus, we plan to perform additional experiments with
cell line and patient-derived xenografts to examine the
effect of the triple combination therapy in vivo. Further,
it has been shown previously that the efficacy and tox-
icity of of Capecitabine is dependent on the enzymatic
activity of Dihydropyrimidine Dehydrogenase, the rate-
limiting 5-FU catabolic enzyme (encoded by DPYD,
reviewed in [65]). Thus, the efficacy and toxicity of the
various capecitabine-based combination therapies will
consequently also depend on the genetic background of
the individual tumor or patient (reviewed in [66]). More-
over, whether CDA expression increases after chemo-
therapy is challenging to determine in vivo since CDA
expression was extremely heterogeneous in tumor tis-
sues of patients (Figure S15, Additional file 1).
Conclusions
In summary, we found that 5′-DFCR, the active metab-
olite of capecitabine, targets intrinsically chemotherapy-
resistant NSCLC cells characterized by high expression
of CDA and TYMP. In addition, we were able to show
that treatment with 5′-DFCR also eradicates cells, which
acquired resistance during the recovery phase after
chemotherapy, e.g. due to increased CDA and TYMP ex-
pression. In other words, we were able to show that
metabolic reprogramming after chemotherapy treatment
becomes a vulnerability of resistant lung cancer cells.
Altough we were not able to fully elucidate the mecha-
nisms underlying the increase in CDA expression, we
were nevertheless able to show that EMT is involved in
the regulation of CDA expression. Thus, our study re-
veals that the chemotherapy-induced increase in pyrimi-
dine salvage pathway expression, e.g., increased CDA
and TYMP, might be exploited in the clinical setting to
target therapy-resistant lung cancer by schedule-
dependent treatment with Capecitabine.
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Additional file 1: Supplementary Figure S1. Mitochondrial
metabolism inhibitors selected to target chemotherapy resistant para
clone cells. A, C Inhibitors targeting different parts of mitochondrial
metabolism IACS-010759 inhibiting Complex I of Electron Transport
Chain, CPI-613 inhibiting pyruvate dehydrogenase ɑ1; Tigecycline, inhibit-
ing mitochondrial ribosome 30S, blocking protein synthesis. B pyrimidine
pathway related inhibitors, teriflunomide, DHODH inhibitor; tetrahydrouri-
dine, CDA inhibitor; 5′-deoxy-5-fluorocytidine, cytidine analogue; D vol-
cano curve based on RNA-seq data between A549 holo and para clone
cells different genes related nucleotide synthesis were shown in the
curve. Mitochondrial gene list (MitoCarta) was used in this curve. Supple-
mentary Figure S2. Metabolic inhibitors selection to target chemother-
apy resistant A549 para clone cells. Cell viability assay (APH assay), Cells
were treated with different inhibitors for 6 days, Holo 1.1: A549 holoclone
1.1 cells; Para 3.7: A549 paraclone 3.7 cells. N = 3, two-way ANOVA was
performed, * p < 0.05, *** p < 0.001, **** p < 0.0001. Supplementary
Figure S3. Silencing of CDA expression increased the fraction of cells
featuring a hybrid-E/M status in the A549 cell line. A Analysis of EMT-
related plasticity by flow cytometry in the A549 cell line 72 h after CDA
siRNA transfection, Holo-, mero-, paraclone, and hybrid cells featured a
CD90−/SOX2+, CD90−/SOX2−, CD90+/SOX2−, and CD90+/Sox2+ expres-
sion phenotype, respectively; B Relative quantification for each subpopu-
lation after CDA siRNA knockdown, N = 2; C Cell cycle analysis of A549
cells after siCTRL and siCDA transfection, N = 2; D DNA damage analysis
by quantification of ɣH2AX expression levels by flow cytometry, The level
of ɣH2AX expression in A549 control cells was set as 10%, N = 2, two
sided student’s t test was used, ns: no significant difference; E Cell
morphology of A549 cells 72 h after transfection with siCTRL and siCDA,
respectively (40×, total magnification). Supplementary Figure S4. High
expression of CDA and TYMP associates with poor prognosis. A and B:
Kaplan-Meier Plots, correlation between CDA, TYMP expression and prog-
nosis of patients after chemotherapy treatment; C: Kaplan-Meier univari-
ate survival analyses of overall survival of TCGA lung adenocarnoma
patients(N = 502), Overall survival(C and D) is analyzed and plotted using
the R ‘survival’ and ‘survminer’ packages. The p-value is calculated by the
log-rank test. Supplementary Figure S5. Basal expression of CDA and
TYMP in different cell lines and CDA and TYMP expression after chemo-
therapy in additional cell lines. A Basal expression level of CDA and TYMP
in different cell lines used in the study; B, C Immunoblotting of CDA and
TYMP in H 2009 cells after schedule chemotherapy treatment, single
treatments and concomitant chemotherapy treatment; D Immunoblot-
ting of CDA and TYMP expression in H 2228 cells after chemotherapy
treatment; E,F Comparison analysis of CDA expression in KRAS WT (FALSE)
and KRAS mutated (TRUE). One hundred eighty-nine lung cancer cell lines
(E) and patient samples from TCGA (F) were used in the analysis. Supple-
mentary figure S6. Quantification analysis of CDA and TYMP after treat-
ment in different cell lines (Fig. 3). A-C Quantification analysis of CDA and
TYMP expression in A549, H358, and H441 cell lines after schedule treat-
ment, N = 2, two-sided student’s t test, (* p < 0.05, **p < 0.01); D-E Quanti-
fication analysis of CDA and TYMP expression in H358 and H441 cell lines
after single MTA, cisplatin and combination treatment, N = 2, two-sided
student’s t test (* p < 0.05, **p < 0.01); F-H Quantification analysis of CDA
and TYMP expression in PC-9, H1993, and H3122 cell lines after schedule
treatment, N = 2, two-sided student’s t test (* p < 0.05, **p < 0.01); I Quan-
tification analysis of TYMP expression in the PC-9 cell line after single
MTA, cisplatin and combination treatment, N = 2, two-sided student’s t
test (* p < 0.05); J and K Quantification analysis of CDA and TYMP expres-
sion in H1993 (J) and H3122 (K) cells after single MTA, cisplatin and com-
bination treatment, N = 2, two-sided student’s t test (* p < 0.05, **p <
0.01). Supplementary Figure S7. Cell response comparison after three
different schedule treatment strategies. A Colony morphology
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comparison after different treatments, A549 cell line: colony morphology
and colony formation assay at recovery day 21 and 27; B Representative
image of counting senescent and normal cells, ‘1’ in red represents a
healthy cell, while ‘2’ in blue represents a senescent cell; C Comparison of
senescent cell ratio after three different schedule treatment regimens,
N = 3. Supplementary Figure S8. gating strategy for cell cycle analysis
and DNA damage. A-C gating strategies for single cells; D-E: Gating strat-
egy to distinguish small and large cells by gating FSC-SSC High and FSC-
SSC low populations; F-G ɣH2AX high gate, set the gate ɣH2AX-High of
untreated sample to 10% as basal level. H Comparison of FSC-SSC high
population in H358 cells after different treatment strategies, N = 2. on
RD11, two-sided student’s t test was performed to compare untreated
group with the other groups, * p < 0.05, *** p < 0.001. On RD18, two-
sides student’s t test was performed to compare the 5′-DFCR only group
with the other three groups, * p < 0.05, ns: no significant difference. 2-
way ANOVA was performed to compare the three groups Schedule,
Schedule + 5′-DFCR D1, and Schedule + 5′-DFCR RD2, ns: no significant
difference. Supplementary Figure S9. Cell cycle distribution of three
different treatment strategies. Cell cycle distribution was analysed in F/S-
low and F/S-high cells Group, respectively. ‘5’-DFCR at recovery day 2′ in-
creased long-term S-phase and G2/M-phase arrest induced by schedule-
dependent treatment. Data are represented as mean ± SD (N = 2). Sup-
plementary Figure S10. Gating strategy for analyzing ɣH2AX and CDA
expression levels within different EMT state. A-C: gating strategies for sin-
gle cells; D: Gating for EMT state including epithelial, meshenchymal, hy-
brid, and negative; E, F: Under the gate ‘single cells’, CDA-High and
ɣH2AX-High were gated, while roughly 10% was set for untreated H358
cells. G, H: From each status of EMT, the same gates ‘CDA-High’ (E) and
‘ɣH2AX-High’ (F) were used to evaluate CDA and ɣH2AX expression levels
within different EMT state; I, H: Percentages of ‘ɣH2AX-High’ and ‘CDA-
High’ in hybrid-EMT status at different time points, after different regimen
treatment. High levels of ɣH2AX and CDA were shown in the hybrid-EMT
status. N = 2, 2-way ANOVA was performed, ns: no significant difference.
Supplementary Figure S11. Schedule+ 5′-DFCR RD2 regimen delayed
the decrease of CDA and ɣH2AX expression levels. A-B: Total CDA and
ɣH2AX expression over time after three regimen treatments, including
schedule, schedule + 5′-DFCR D0, and schedule + 5′-DFCR RD2, N = 2,
two-way ANOVA was performed, * p < 0.05, ns: no significant difference;
C,D: Untreated H 358 cells at Hybrid-EMT harbored higher expression of
CDA and ɣH2AX, compared with other EMT state, N = 2, one-way ANOVA
was performed to compare mesenchymal, hybrid, and negative with the
epithelial population, ** p < 0.01, *** p < 0.001; E, F: On recovery day 26
(RD26) after treatment of different regimens, CDA and ɣ H2AX levels of H
358 cells at different EMT states, N = 2, one way ANOVA was performed
to compare mesenchymal, hybrid, and negative with the epithelial popu-
lation, * p < 0.05. Supplementary Figure S12. DNA damage persistence
during recovery phase after chemotherapy treatment in different cell
lines A Immunoblotting of CDA, EMT markers and DNA damage marker
p-H2AX expression in H 2009 cells after chemotherapy treatment; B-C Im-
munoblotting of CDA, TYMP and p-H2AX expression in H358 and H441
cells after chemotherapy treatment; D: morphology change H358 cells
after MTA and cisplatin combination chemotherapy treatment at recovery
day 5 (40×, total magnification). Supplementary Figure S13. No correl-
ation of CDA expression an clinico-pathologic characteristics. A: No correl-
ation of CDA expression and the pT stage of the tumors (109 samples
included, Spearman correlation, p = 0.893); B: No correlation of CDA ex-
pression and the pN stage of the tumors, all primary resected samples
were excluded due to a minimum pN2 (49 samples included, Spearman
correlation p = 0.792). Supplementary Figure S14. Representative im-
munohistochemical CDA staining in patient tissues and A549 cells. A-D:
Intensity scoring of CDA expression: A strong; B moderate; C weak; D
negative sample; E-F Establishment of CDA staining protocol with A549
holo and para clone cells. Supplementary Figure S15. Heterogeneous
CDA expression in patient tumor tissues. A Heterogeneity within the
same TMA core, B-C: Heterogeneity in two different TMA cores of the
same case; D, G: Heterogeneous CDA expression in two different cases; E,
F: heterogeneity in two different TM -cores of the same case; H: Number
of homogeneous and heterogeneous CDA-staining patterns in 109 pa-
tient tumor tissues (Fisher’s exact p = 0.228).
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